Gemini Scientists

Pipeline

Our research pipeline is designed to develop treatments for genetically defined subpopulations of patients suffering from dry AMD and linked diseases. This could provide patients with access to targeted first-in-class medicines for patients with limited therapeutic options.

Precision Medicine Pipeline

Age-Related Macular Degeneration

Target
Indication/Modality
Preclinical
IND-Enabling
Phase 1
Phase 2
Phase 3
GEM103 – Dry AMD, Geographic Atrophy

Modality: Recombinant Proteins IconRecombinant CFH Protein

Status: Phase 2


Systemic Renal

Target
Indication/Modality
Preclinical
IND-Enabling
Phase 1
Phase 2
Phase 3
GEM307

Modality: Monoclonal Antibodies IconPotentiating Antibody

Status: IND-Enabling